SFI
ATOS icon

Susquehanna Fundamental Investments’s Atossa Therapeutics ATOS Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,319
Closed -$29K – 1201
2022
Q3 		$29K Buy
+2,319
New +$33.7K ﹤0.01% 1389
2022
Q1 		$140K Sell
7,460
-1,201
-14% -$24.4K ﹤0.01% 1419
2021
Q4 		$208K Buy
8,661
+2,331
+37% +$85.3K 0.01% 1237
2021
Q3 		$310K Buy
+6,330
New +$368K 0.01% 1396
2020
Q4 		– Sell
-1,127
Closed -$41K – 1493
2020
Q3 		$41K Buy
+1,127
New +$54.1K ﹤0.01% 1326

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Susquehanna Fundamental Investments's ATOS Position: Q4 2022 in Review

Susquehanna Fundamental Investments sold out of Atossa Therapeutics (ATOS) in Q4 2022, closing a stake of 2,319 shares — an estimated $29K sold.

Susquehanna Fundamental Investments first reported a position in ATOS in Q3 2020 and held it in 5 quarters. The position peaked at $310K in Q3 2021. 51 funds tracked by Wall St. Rank hold ATOS as of Q4 2022.

  • Susquehanna Fundamental Investments reported no remaining Atossa Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 2,319 Atossa Therapeutics shares in Q4 2022, an estimated $29K.
  • Susquehanna Fundamental Investments first reported a position in Atossa Therapeutics in Q3 2020 and held it in 5 quarters.
  • Susquehanna Fundamental Investments's Atossa Therapeutics position peaked at $310K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2022, filed 14 Feb 2023.